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CLUSIONS: Five methods of measuring BLISS attainment using
four pre-speciﬁed threshold levels of pain were able to statisti-
cally discriminate between treatment groups. This method may
potentially provide an approach, to deﬁning which patients not
only improve but also achieve a good state of health, at low and
very low levels of pain intensity. BLISS -10 is a therapeutically
attainable very low symptom state at which clinically important,
statistically signiﬁcant between group differences are detectable,
and therefore may provide a benchmark against which thera-
peutic interventions can be assessed. However, the value to
patients, of this and other low and very low intensity pain states,
requires further elaboration.
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OBJECTIVE: To evaluate osteoarthritis (OA) patients’ ability to
state valid preferences for tradeoffs between treatment-related
serious adverse events (SAEs) and speciﬁed treatment beneﬁts.
METHODS: A web-enabled, choice-format, conjoint or stated-
preference survey was developed to elicit OA patients’ willing-
ness to accept tradeoffs between SAE probabilities and treatment
efﬁcacy. The treatment attributes included in the tradeoff tasks
employed graphical elements indicating pain and stiffness sever-
ity on a continuous visual analog scale, mild-to-moderate gas-
trointestinal (GI) symptoms measured by type of intervention
required, and bleeding ulcer, heart infarct, and stroke probabil-
ities shown numerically and visually on a 100-square grid. The
instrument was pretested with a convenience sample of 8 OA
patients and administered to a sample of OA patients in a large-
scale pilot survey. Random-parameter logit estimates were used
to calculate maximum acceptable 10-year MAR various levels of
clinical beneﬁt. RESULTS: A total of 156 patients completed the
pilot survey. Only 4% of subjects failed the irrational-choice and
14% failed the cross-question monotonicity internal validity
tests. Patients discriminated successfully among pain and SAE
risk levels. Mild-to-moderate gastrointestinal side effects had no
signiﬁcant effect on treatment choices. Pain control was about
twice as important as control of stiffness, and stroke likelihood
was the most important SAE risk. Maximum acceptable risk
(MAR) increased as expected with greater therapeutic beneﬁts
and decreased inversely with the importance of SAE risks. Mean
MAR for a maximal improvement from moderate daily symp-
toms to full symptom control was signiﬁcantly greater than 0.05
for ulcer, infarct, and stroke (p < 0.001 for all). CONCLU-
SIONS: All medical interventions carry risks of adverse outcomes
that must be evaluated against their clinical beneﬁts. OA patients
in this pilot study indicated they were willing to accept SAE risks
in excess of clinical levels for sufﬁciently large improvements in
symptom control.
ARTHRITIS—Patient Reported Outcomes
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A COMPARISON OF HEALTH RELATED QUALITY OF LIFE
(HRQOL) OF PERSONS WITH AND WITHOUT ARTHRITIS OR
CHRONIC JOINT SYMPTOMS (CJS)
Tagliavia NA, Kamal KM, Desselle SP
Duquesne University, Pittsburgh, PA, USA
OBJECTIVES: To characterize health related quality of life
(HRQoL) among persons with and without arthritis or chronic
joint symptoms (CJS). METHODS: Data obtained from the
2004 Behavioral Risk Factor Surveillance Survey (BRFSS), an
ongoing, state-based, random-digit-dialed telephone survey of
non-institutionalized persons aged >/= 18 years conducted in all
states. Data from nine states (54,116 participants) were included
in the analysis as these states had included both components of
arthritis and HRQoL measures (mental, physical, and poor
health) in the 2004 survey. Multiple linear regression analyses
were used to examine the associations between selected sociode-
mographic and behavioral determinants and HRQoL among
participants with arthritis or CJS. RESULTS: Of the respondents
32% had been diagnosed with some form of arthritis by a health
care professional and 46% had joint pain in the past 30 days.
The respondents with arthritis had a mean of 6.75 physically and
4.58 mentally unhealthy days and 6.41 poor health days during
the past 30 days compared with 2.29, 3.14, and 2.76 among
those without arthritis. Only 36.9% of participants with arthri-
tis reported very good general health versus 60.9% of respon-
dents without arthritis (p = 0.000). For each unit of age increase
of participants with arthritis there was an increase in physical,
mental, and poor unhealthy days. Based on WHO’s classiﬁcation
of obesity, the respondents with arthritis included approximately
30.9% normal weight, 37.3% overweight, 27% obese, and
4.7% severely obese respondents. Regression analysis indicated
that severely obese, obese, and over weight experienced more
unhealthy physical and poor days than respondents with normal
weight. Active men and women were less likely to report poor
unhealthy days compared with those who did not exercise in the
past 30 days. CONCLUSIONS: Findings indicate that persons
with arthritis or CJS experience a decrease in HRQOL as com-
pared to those without arthritis.
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OBJECTIVES: Osteoarthritis is prevalent and debilitating
disease that affects nearly 21 million Americans. For clinicians
to assess the impact of treatment strategies require reliable, valid
and interpretable measures. We conducted a systematic review
of WOMAC which is a disease speciﬁc instrument measuring
HRQL of patients with osteoarthritis. The review considered the
evaluative, discriminative properties and interpretability of the
instrument. The last systematic review was published in 2001.
METHODS: A structured literature review was performed to
identify evidence related to measurement properties (reliability,
internal consistency, responsiveness, and interpretability) of
WOMAC using two databases (MEDLINE and HealthSTAR)
from 1982 to December 2005. We included randomized con-
trolled trials and observational studies. RESULTS: Of 307 and
137 papers, 14 met the inclusion criterion. Discriminative: We
found high reliability (correlation coefﬁcients) for domains of
pain and physical function (>0.7), compared to the stiffness
domain (>0.6). All domains had generally high construct valid-
ity in differentiating among patients with better/worse HRQL.
The internal consistency (Cronbach’s alpha) was high (>0.8).
WOMAC generally had high construct validity. Responsiveness
varied by domain and by intervention. WOMAC was more
responsive in patients who underwent total hip or knee arthro-
plasty compared to other interventions. We found that the phys-
ical function domain was more responsive than other domains
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and this was more evident in patients with arthroplasty. The
minimal score difference on 0–10 scale needed to detect clinical
improvement (worsening) was 0.64(0.75), 1.03(0.67), and
0.29(0.72) for pain, physical function, and stiffness domain,
respectively. CONCLUSIONS: WOMAC has good discrimina-
tive and evaluative properties. These properties provide an
opportunity to measure new health technologies and other inter-
ventions in this cohort of patients with conﬁdence. To beneﬁt
from the use of this measure as an interpretable one we 
need additional research in patients, particularly within 
clinical trials where other objective and interpretable measures
are used.
PAR19
ities (preferences) for 5 beneﬁt characteristics (route, physician
experience, onset, chance of beneﬁt, bone erosions), 6 common
adverse effects (injection site reaction, rash, oral ulcers, alopecia,
nausea, diarrhea), 4 rare adverse effects (cancer, nephrotoxicity,
hepatotoxicity, pneumonitis), and 1 cost characteristic (monthly
co-pay) were estimated using adaptive conjoint analysis. The 16
characteristics were based on four treatment choices: methotrex-
ate, gold, leﬂunomide, and etanercept. Based on the estimated
utilities for the 16 characteristics, the marginal rates of sub-
stitution between pairs of characteristics were computed.
RESULTS: Multiple BRC trade-off utilities were calculated and
will be presented. A subset of three of these BRC trade-off util-
ities is presented below. The utility lost by patients switching
from oral to subcutaneous injection was equal to the utility
gained from: incidence of rash decreasing from 40% to 9.5%;
nausea decreasing from 30% to 6.5%; diarrhea decreasing from
30% to 10.4%; or monthly co-pay lowered from $30 to $7.14.
For chance of beneﬁt versus onset trade-off, the range was from
-0.086 weeks/% (0.086 weeks of delay in the onset of the drug,
for a 1% increase in the chance of beneﬁt) to -0.244 weeks/%.
For onset versus diarrhea trade-off, the range was from 
-2.08%/week (2.08% reduction in the incidence of diarrhea, for
a one week delay in onset) to -7.23%/week. CONLCLUSIONS:
Patient preferences can be used to make explicit, the latent trade-
off decisions made by patients at the characteristics level in arriv-
ing at treatment choice decisions. This study methodology can
also be used to understand physician preferences for treatment
choices.
DIABETES—Clinical Outcomes Studies
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PREVIOUSLY INSULIN-NAIVE U.S. MANAGED CARE PATIENTS
WITH TYPE 2 DIABETES
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1Eli Lilly and Company, Indianapolis, IN, USA, 2Healthcore, Inc,
Wilmington, DE, USA
OBJECTIVES: Patient characteristics, treatment patterns, and
clinical effectiveness were assessed for insulin naïve patients with
type 2 diabetes (T2D) who initiated treatment with insulin
glargine. METHODS: Administrative and pharmacy claims were
linked with laboratory results from a large managed care data-
base and were analyzed between May 1, 2001 and May 31,
2004. Patients with a diagnosis of T2D who were insulin-naïve
prior to ﬁlling prescriptions for glargine were selected for analy-
sis and followed for a minimum of 12 months. The initial claim
for glargine served as the index date. Other antidiabetic therapy
was assessed for the month prior to the index date. Glargine
treatment patterns included persistence and concomitant med-
ications. A subset of patients receiving HbA1c results both
within 90 days pre- and no sooner than 60 days post-index
periods were analyzed for HbA1c changes. RESULTS: A total of
936 insulin-naïve patients with T2D who initiated glargine
therapy were identiﬁed. Prior to starting glargine, 50% of
patients received no antidiabetic therapy, 21% received oral
antidiabetic monotherapy, and 29% received combination oral
therapy. Post-index, 20% of patients received glargine alone,
while 80% received glargine in combination with short-acting
insulin (38%) and/or oral antidiabetic agents (42%). The
average length of glargine therapy was 185 days until a change
in the index therapy occurred. In patients with both pre-and
post-index values (N = 49), HbA1c decreased from 8.7% to
7.6% post-index (p = 0.0003). The average length of time
between index and post-index HbA1c measurement was 216
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BENEFIT-RISK-COST TRADE-OFF ANALYSES USING PATIENT
PREFERENCES FOR THE TREATMENT OF RHEUMATOID
ARTHRITIS
Arjunji RV, Dabbous OH, Rahman MI
Centocor, Inc, Horsham, PA, USA
OBJECTIVE: To estimate the beneﬁt-risk-cost (BRC) trade-off
at the patient level, utilizing patient preferences for treatment
choices in rheumatoid arthritis (RA). METHODS: Published
patient preferences on 120 RA patients with mean disease dura-
tion of 8 years was used to conduct these trade-off analyses. Util-
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